The successful clinical application of monoclonal antibodies (mAbs) against checkpoint regulators like PD1/PD-L1 and CTLA-4 has transformed the field of cancer immunotherapy [42]; however, their effect on iNKT cells remains to be fully elucidated. Here, CTLA4 is linked to cancer.